Poor prognosis and SATB1 overexpression in solid tumors: a meta-analysis
Authors Wang S, Zeng J, Xiao R, Xu G, Liu G, Xiong D, Ye Y, Chen B, Wang H, Luo Q, Huang Z
Received 14 February 2018
Accepted for publication 21 March 2018
Published 8 June 2018 Volume 2018:10 Pages 1471—1478
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Leylah Drusbosky
Shengjie Wang,1,* Junjie Zeng,1,* Rui Xiao,2,* Guoxing Xu,3,* Gang Liu,1 Disheng Xiong,2 Yongzhi Ye,1 Borong Chen,1 Haibin Wang,2 Qi Luo,1 Zhengjie Huang1,2
1Department of Gastrointestinal Surgery, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China; 2Department of Gastrointestinal Surgery, First Clinical Medical College of Fujian Medical University, Fuzhou, People’s Republic of China; 3Department of Endoscopy Center, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China
*These authors contributed equally to this work
Background: Several previous studies have reported the prognostic value of special AT-rich sequence-binding protein 1 (SATB1) in solid tumors. However, these studies produced inconsistent results because of their various limitations, including small sample sizes. Here, we describe a meta-analysis based on 17 studies including 3144 patients to search for connections between SATB1 overexpression and overall survival (OS) of patients with solid tumors. Seventeen studies (n = 3144) were assessed in the meta-analysis. Both univariate and multivariate analysis for survival indicated that high SATB1 reactivity significantly predicted poor prognosis. In the multivariate analysis, the combined hazard ratio (HR) for OS was 1.82 (95% confidence interval [CI]: 1.59–2.08, P < 0.0001). The pooled HR of the univariate analysis for OS was 1.96 (95% CI: 1.65–2.34, P < 0.0001).
Methods: Studies were identified by an electronic search of PubMed, EMBASE, and Web of Science, including publications prior to April 2017. Pooled HR values for OS were aggregated and quantitatively analyzed in the meta-analysis.
Conclusion: The meta-analysis indicated that high SATB1 reactivity is significantly correlated with decreased survival in most cases of solid tumors. In addition, SATB1 shows promise as a prognostic biomarker and novel therapeutic target on the basis of its expression level in solid tumors.
Keywords: SATB1, prognosis, solid tumor, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]